Search | Clinical Trials Finder

Conditions: Uncontrolled Hypertension
Interventions: RTN-001, Matching placebo control; Drug
Lead sponsor: Retension Pharmaceuticals. Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 34
States / cities: Alexander City, Alabama • Birmingham, Alabama • Tucson, Arizona + 30 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 74
States / cities: Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more

Conditions: Gastro Esophageal Reflux
Interventions: Esophageal studies; Diagnostic Test
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Ovarian Cancer
Interventions: filgrastim, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14; Biological · Procedure · Radiation
Lead sponsor: Garden State Cancer Center at the Center for Molecular Medicine and Immunology; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 3
States / cities: Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania

Conditions: Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
Interventions: Placebo, LX211; Drug
Lead sponsor: Lux Biosciences, Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 16 more

Conditions: Overweight, Obese
Interventions: Exercise Energy Expenditure 300 kcal/day, Exercise Energy Expenditure 600 kcal/day; Other
Lead sponsor: USDA Grand Forks Human Nutrition Research Center; Federal
Eligibility: 18 Years to 40 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Grand Forks, North Dakota

Conditions: Dental Pain
Interventions: Maxigesic 325, Acetaminophen, Ibuprofen, Placebo; Drug
Lead sponsor: AFT Pharmaceuticals, Ltd.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Morbid Obesity
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 2
States / cities: Sacramento, California • Reno, Nevada

Conditions: Type 2 Diabetes
Interventions: low carb diet, diabetic diet; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 12 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Psoriasis Vulgaris, Psoriasis
Interventions: tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g, placebo ointment (vehicle); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 29
States / cities: Hot Springs, Arkansas • Bakersfield, California • Irvine, California + 22 more

Conditions: Papulopustular Rosacea, Erythematotelangiectatic Rosacea
Interventions: Reference: Metronidazole Gel 1%, Test: Metronidazole Gel 1%, Placebo Gel; Drug
Lead sponsor: bioRASI, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 963 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 27
States / cities: Los Angeles, California • San Diego, California • Boca Raton, Florida + 23 more

Conditions: Asthma
Interventions: Experimental: Standard vs Intensive e-AT Intervention; Other
Lead sponsor: University of Utah; Other
Eligibility: 2 Years to 17 Years
Enrollment: 926 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Narcolepsy, Excessive Daytime Sleepiness, Cataplexy Narcolepsy
Interventions: mazindol extended release, Placebo; Drug
Lead sponsor: NLS Pharmaceutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 22
States / cities: Birmingham, Alabama • Redwood City, California • San Diego, California + 17 more

Conditions: Acute Pain
Interventions: Pain control regimens; Other
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prostate Cancer
Interventions: 1.5 T Elekta Unity MR-Linac system, Hydrogel rectal spacer (SpaceOAR); Radiation · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Dry Eye Syndromes
Interventions: SJP-0035 0.001%, Placebo; Drug
Lead sponsor: Senju Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 23
States / cities: Chandler, Arizona • Sun City, Arizona • Long Beach, California + 20 more

Conditions: Healthy Volunteer
Interventions: Placebo, RO5508887; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: Insulin-like Growth Factor-1 Deficiency
Interventions: NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]); Drug
Lead sponsor: Ipsen; Industry
Eligibility: 5 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Hypoparathyroidism, Chronic Hypoparathyroidism
Interventions: Encaleret, Placebo; Drug
Lead sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company; Industry
Eligibility: 16 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 4
States / cities: Reno, Nevada • Greenville, North Carolina • Morehead City, North Carolina + 1 more

Conditions: Asthma
Interventions: FF, Placebo, Montelukast, Albuterol/Salbutamol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 14
States / cities: Little Rock, Arkansas • Alhambra, California • Costa Mesa, California + 8 more

Conditions: Asthma
Interventions: MAP0010 low dose, MAP0010 high dose, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: San Diego, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Promoting Resilience in Stress Management (PRISM); Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 13 Years to 18 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Houston, Texas • Seattle, Washington

Conditions: Hemorrhage
Interventions: TachoSil, Surgicel Original; Biological
Lead sponsor: Corza Medical GmbH; Industry
Eligibility: 1 Month and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Torrance, California • Lakewood, Colorado • Washington D.C., District of Columbia + 6 more

Conditions: Healthy
Interventions: Single-Dose IV Oritavancin Diphosphate, Placebo, Moxifloxacin; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: West Bend, Wisconsin

Search by objective public record fields.

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Esophageal and Gastric Registry and Biorepository

Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer

A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis

Exercise and Weight Control

Maxigesic 325 Acute Dental Pain Study

Neurohumoral Control of Intestinal Electrical and Mechanical Activity

A Low-Carb Approach to Treat Type 2 Diabetes in Pediatric Patients

Tofacitinib Ointment For Chronic Plaque Psoriasis

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

Redesigning Ambulatory Care Delivery to Enhance Asthma Control in Children

Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy

Evaluation of the Analgesic Efficacy of Multimodal Pain Control Regimens That Aim to Limit the Use of Narcotics in Cholecystectomy and Hernia Repairs

Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy

A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease

A Pharmacodynamic and Pharmacokinetic Study of RO5508887 in Healthy Volunteers

rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency

Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism

Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma

Study of MAP0010 in Asthmatic Children and Adolescents

PRISM for Adolescents With Type 1 Diabetes

A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery

A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants